Moving targets in a static genome: The challenge of variant reclassification

Hypertrophic cardiomyopathy (HCM) is one of the most frequent “rare” inherited cardiac conditions, affecting roughly 1 in 500 individuals, and is often regarded as a paradigm condition for the application of clinical genomics. Since the discovery of the first disease-causing variant, MYH7 :p.Arg403Gln, in 1990 [ 1 ], genetic testing has become widely adopted and matured to the point where a positive result guides clinical decisions, especially for family screening through predictive cascade testing. Often times, for the sake of routine clinical practice, the result is dichotomised into actionable, (likely) pathogenic (LP, P) variants, or non-actionable: variants of uncertain significance (VUS), (likely) benign (LB, B) variants or no variants of interest. However, one could wonder what’s the warranty period of a result? We are used to challenging VUS periodically, but should we do the same for apparently disease-causing variants?

Authors

Institutions

Publication Details

Journal
European Journal of Human Genetics
Published
2026-11-14
DOI
https://doi.org/10.1038/s41431-026-02269-6
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Moving targets in a static genome: The challenge of variant reclassification

Roddy Walsh, Mihnea Casian
European Journal of Human Genetics
Genomics and Rare Diseases
article

Moving targets in a static genome: The challenge of variant reclassification

Roddy Walsh, Mihnea Casian
article en

Abstract

Hypertrophic cardiomyopathy (HCM) is one of the most frequent “rare” inherited cardiac conditions, affecting roughly 1 in 500 individuals, and is often regarded as a paradigm condition for the application of clinical genomics. Since the discovery of the first disease-causing variant, MYH7 :p.Arg403Gln, in 1990 [ 1 ], genetic testing has become widely adopted and matured to the point where a positive result guides clinical decisions, especially for family screening through predictive cascade testing. Often times, for the sake of routine clinical practice, the result is dichotomised into actionable, (likely) pathogenic (LP, P) variants, or non-actionable: variants of uncertain significance (VUS), (likely) benign (LB, B) variants or no variants of interest. However, one could wonder what’s the warranty period of a result? We are used to challenging VUS periodically, but should we do the same for apparently disease-causing variants?

European Journal of Human Genetics
St George's, University of London (GB), St George’s University Hospitals NHS Foundation Trust (GB), City St George's, University of London (GB)
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon